<DOC>
	<DOCNO>NCT00354016</DOCNO>
	<brief_summary>Due antigenic change influenza virus , virus strain use influenza vaccine adjust every year accord WHO ( World Health Organization ) CHMP ( Committee Medicinal Products Human Use ) recommendation . Immunogenicity tolerability newly compose vaccine subject evaluation yearly clinical trial non-elderly elderly subject ( CPMP/BWP/214/96 ) .</brief_summary>
	<brief_title>Safety Immunogenicity Preservative Free Inactivated Split Influenza Vaccine , Using Strain Composition 2006/2007 Non-Elderly Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult age &gt; 18 year serious chronic disease significant acute infection require systemic antibiotic treatment history anaphylaxis , serious vaccine reaction hypersensitivity vaccine component history neurological symptom sign , anaphylactic shock follow administration vaccine know suspected impairment/alteration immune function one injection influenza vaccine receive laboratory confirm influenza disease within last 6 month : influenza vaccination receive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>influenza</keyword>
	<keyword>vaccine</keyword>
</DOC>